Last update: June 10, 2018
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
A recombinant fusion protein that suppresses neovascularization and decreases vascular permeability.
Used to treat forms of macular degeneration and edema and myopic choroidal neovascularization via intravitreal injection.
Since the last update we have not found published data on its excretion in breast milk.
Following intravitreal administration, plasma concentrations at 1-3 days are low (0 to 0.05 microngram/mL) and undetectable at 2 weeks. This concentration is between 50 and 500 times lower than necessary to have some systemic effect. In addition, it binds to the vascular endothelial growth factor forming an inert complex that, like other proteins, is degraded by protein catabolism. It does not accumulate after repeated doses every 4 weeks (EMA 2017).
Its very high molecular weight makes it very unlikely that it will transfer into milk.
Due to its protein nature it is inactivated in the gastrointestinal tract, not being absorbed, so its oral bioavailability is practically nil, except in premature babies and the immediate neonatal period when there may be greater intestinal permeability.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM